The Johns Hopkins Greenberg Bladder Cancer Institute was established in May 2014 and is a co-investment of Erwin and Stephanie Greenberg with The Johns Hopkins University.
The Johns Hopkins Greenberg Bladder Cancer Institute, based in Baltimore, Maryland, is the first of its kind that is dedicated to improving the lives and outcomes of patients with bladder cancer and their families. In May 2014, the Institute was established with a $15 million gift from Baltimore-area commercial real estate developer Erwin L. Greenberg and his wife, Stephanie Cooper Greenberg — part of a $45 million co-investment with The Johns Hopkins University.
Read more about our goals in the Greenberg Bladder Cancer Institute Case Statement.
Make a Gift
The Institute was inspired by the tens of thousands of men and women diagnosed with bladder cancer each year. For 50 years, there has been little new to offer patients, but that is changing. As part of the revolution in bladder cancer research and clinical discovery, our team is bringing gene therapy, immunotherapy, targeted therapies, tumor sequencing, clinical trials, drug development and other innovations, all for the benefit of bladder cancer patients.
We strive to be a collaborative virtual network that draws upon the world’s best expertise — from Johns Hopkins and beyond — to further the scientific understanding of bladder cancer and develop new methods for preventing, treating and curing the disease. Our multidisciplinary research teams include experts from the Johns Hopkins Kimmel Cancer Center and James Buchanan Brady Urological Institute, as well as faculty members from the Johns Hopkins University School of Medicine’s departments of Radiation Oncology and Molecular Radiation Sciences, Pathology, and Surgery.